Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.

Jendrzejewski J, Tomsic J, Lozanski G, Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT, Heerema NA, de la Chapelle A.

J Clin Endocrinol Metab. 2011 Nov;96(11):E1876-80. doi: 10.1210/jc.2011-1643. Epub 2011 Sep 7.

2.

Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients.

Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, Durante C, Pacini F.

J Clin Endocrinol Metab. 2008 Oct;93(10):3950-7. doi: 10.1210/jc.2008-0372. Epub 2008 Jul 29.

PMID:
18664542
3.

Lack of mutations of the telomerase RNA component in familial papillary thyroid cancer with short telomeres.

Cantara S, Capuano S, Capezzone M, Benigni M, Pisu M, Marchisotta S, Pacini F.

Thyroid. 2012 Apr;22(4):363-8. doi: 10.1089/thy.2011.0109. Epub 2012 Feb 3.

PMID:
22304389
4.

Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer.

Capezzone M, Cantara S, Marchisotta S, Busonero G, Formichi C, Benigni M, Capuano S, Toti P, Pazaitou-Panayiotou K, Caruso G, Carli AF, Palummo N, Pacini F.

J Clin Endocrinol Metab. 2011 Nov;96(11):E1852-6. doi: 10.1210/jc.2011-1003. Epub 2011 Aug 24.

PMID:
21865371
5.

Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.

Caria P, Cantara S, Frau DV, Pacini F, Vanni R, Dettori T.

Int J Mol Sci. 2016 Oct 21;17(10). pii: E1759.

6.

Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer.

Cantara S, Pisu M, Frau DV, Caria P, Dettori T, Capezzone M, Capuano S, Vanni R, Pacini F.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1327-31. doi: 10.1210/jc.2011-2096. Epub 2012 Apr 26.

PMID:
22539583
7.

Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer.

He M, Bian B, Gesuwan K, Gulati N, Zhang L, Nilubol N, Kebebew E.

Thyroid. 2013 Mar;23(3):301-7. doi: 10.1089/thy.2012.0270.

8.

In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.

Chou SJ, Chen CM, Harn HJ, Chen CJ, Liu YC.

J Surg Res. 2001 Jul;99(1):75-83.

PMID:
11421607
9.

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.

Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D.

Oncogene. 2014 Oct 16;33(42):4978-84. doi: 10.1038/onc.2013.446. Epub 2013 Oct 21.

PMID:
24141777
10.

Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.

Wang N, Xu D, Sofiadis A, Höög A, Vukojević V, Bäckdahl M, Zedenius J, Larsson C.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1571-9. doi: 10.1210/jc.2014-1158. Epub 2014 Apr 23.

11.

Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.

Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Shimamoto F, Sueda T, Hiyama E.

J Gastrointest Surg. 2008 Jan;12(1):17-28; discussion 28-9.

PMID:
17960465
12.

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.

Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R, Hayashi T, Arakawa A, Yao T.

Virchows Arch. 2016 Dec;469(6):687-696. Epub 2016 Oct 7.

PMID:
27718012
13.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

14.

Telomerase activity and telomere length in benign and malignant human thyroid tissues.

Kammori M, Takubo K, Nakamura K, Furugouri E, Endo H, Kanauchi H, Mimura Y, Kaminishi M.

Cancer Lett. 2000 Oct 31;159(2):175-81.

PMID:
10996729
15.

Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome.

Du HY, Idol R, Robledo S, Ivanovich J, An P, Londono-Vallejo A, Wilson DB, Mason PJ, Bessler M.

Aging Cell. 2007 Oct;6(5):689-97.

16.

Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli.

Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Malchoff DM.

Thyroid. 1999 Mar;9(3):247-52.

PMID:
10211600
17.

Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome.

Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, Arnold A, Malchoff DM.

J Clin Endocrinol Metab. 2000 May;85(5):1758-64.

PMID:
10843148
18.

Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population.

Dai J, Cai H, Zhuang Y, Wu Y, Min H, Li J, Shi Y, Gao Q, Yi L.

Respirology. 2015 Jan;20(1):122-8. doi: 10.1111/resp.12422. Epub 2014 Oct 23.

19.

TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.

Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, Alzahrani AS.

Endocr Relat Cancer. 2015 Dec;22(6):901-8. doi: 10.1530/ERC-15-0396. Epub 2015 Sep 9.

20.

Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.

Lee HW, Park TI, Jang SY, Park SY, Park WJ, Jung SJ, Lee JH.

Medicine (Baltimore). 2017 Feb;96(5):e5766. doi: 10.1097/MD.0000000000005766.

Supplemental Content

Support Center